Iversen P, Rose C, Stage J G, Iversen H G, Hansen R I, Hvidt V, Mogensen P, Pedersen T, Hansen J B
Department of Urology, Hvidovre Hospital, Denmark.
Scand J Urol Nephrol. 1989;23(3):177-83. doi: 10.3109/00365598909180838.
An LHRH agonist, Zoladex, was employed as a monthly depot in 56 previously untreated patients with advanced carcinoma of the prostate. Of 53 evaluable patients, 27 achieved partial remission and 7 were stable. Median duration of response was 10 months. A favorable subjective response was attained in 68% of the patients. During treatment, serum testosterone was in the castrate range in all patients except five. Possible explanations for this escape phenomenon are discussed. No toxicity was observed and treatment was well tolerated in all patients. Thirty-two patients underwent bilateral orchiectomy following treatment failure of Zoladex. In one patient partial remission according to protocol criteria was recorded. Treatment with LHRH agonists seems safe and may serve as an alternative to conventional hormonal treatment of advanced carcinoma of the prostate.
一种促黄体生成素释放激素（LHRH）激动剂——戈舍瑞林，被用作56例既往未接受治疗的晚期前列腺癌患者的每月长效注射剂。在53例可评估的患者中，27例获得部分缓解，7例病情稳定。缓解的中位持续时间为10个月。68%的患者获得了良好的主观反应。治疗期间，除5例患者外，所有患者的血清睾酮均处于去势水平。文中讨论了这种逃逸现象的可能解释。未观察到毒性反应，所有患者对治疗耐受性良好。32例患者在戈舍瑞林治疗失败后接受了双侧睾丸切除术。根据方案标准，有1例患者记录为部分缓解。LHRH激动剂治疗似乎是安全的，可作为晚期前列腺癌传统激素治疗的替代方法。
